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Objectives: To assess the cost-effectiveness of quadrivalent influenza vaccine 
(QIV) compared to trivalent vaccine (TIV) in the Italian population aged 65 years or 
more or at high-risk for influenza. MethOds: A static and multi-cohort Markov 
model was modified to simulate the disease process of influenza (type A and B) over 
a lifetime horizon using annual cycles. Several cohorts based on the Italian popu-
lation (nine different age-groups and two level of risks: high and low) entered the 
model and could be vaccinated with QIV or TIV. Vaccine coverage rate, epidemiologi-
cal and demographic estimates were taken from local statistics, surveillance data 
and Italian published studies, while circulation of type A versus B virus and type of 
lineage was taken from Euroflu estimates (from 2003-2004 to 2012-2013). Vaccine 
efficacy against influenza A and B were taken from 2 meta-analyses of clinical trials. 
Costs and resource use were based on local tariffs and published estimates (price 
year 2013). Quality of life scores were obtained from a Spanish study, using the EQ-5D 
questionnaire. The perspective of the National Health Service (NHS) was used and a 
3% discount rate was applied to costs and benefits, according to Italian guidelines. 
To deal with the issue of uncertainty both deterministic and probabilistic sensitivity 
analyses were conducted. Results: In the basecase, the incremental cost per QALY 
and per LY saved for QIV versus TIV were € 10,940 and € 9,452, respectively. The most 
sensitive parameters were vaccine efficacy and probability of circulation of virus 
A versus B, but the probabilistic analysis showed that at a threshold of € 50,000 per 
QALY, there was about 90% probability for QIV to be cost-effective. cOnclusiOns: 
This study suggests that the introduction of QIV at the same level of price of the 
most recent adjuvated vaccines is likely to be a cost-effective strategy from the 
perspective of the Italian NHS.
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Objectives: Chickenpox, or varicella, is a highly communicative infectious dis-
ease affecting mainly young children. Varicella is self-limiting in the majority 
of cases, yet serious complications, including secondary bacterial infections of 
skin and soft tissues, pneumonia and encephalitis, can occur and result in hos-
pitalization. Varicella vaccine is an effective post-exposure prophylaxis (PEP) of 
chickenpox. This study aimed to analyze cost-effectiveness of PEP using varicella 
vaccine for pediatric patients from the perspective of public health care provider in 
Hong Kong. MethOds: A decision tree was designed to compare cost and clinical 
outcomes of PEP with varicella vaccine versus no PEP in pediatric patients (aged 
1-18 years old) susceptible to chickenpox with household exposure. Two tiers of 
outcomes were simulated: 1) Total direct medical cost, and 2) the quality-adjusted 
life year (QALY) loss associated with chickenpox. Model inputs were retrieved from 
local epidemiology and medical literature. Sensitivity analysis was performed on 
all parameters to test the robustness of model results. Results: Base-case analy-
sis showed PEP with varicella vaccine to be less costly (expected cost USD320 vs. 
USD731) with lower QALY loss (0.00423 QALYs vs. 0.01122 QALYs), comparing to no 
PEP. Sensitivity analysis showed that PEP with varicella vaccine was less costly if 
PEP effectiveness was > 6.2% or chickenpox infection rate without PEP was > 8.6%. 
In 10,000 Monte Carlo simulations, PEP with vaccine was cost-effective in over 
99% of the time with mean cost saving of USD611per patient (95% CI USD602-620; 
P< 0.001) and lower mean QALY loss of 0.00809 QALYs (95% CI 0.00802-0.00816 
QALYs; P< 0.001). cOnclusiOns: Using varicella vaccine as PEP seems to be a 
cost-saving strategy to avert QALY loss in susceptible pediatric patients exposed 
to chickenpox in Hong Kong.
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Objectives: Sofosbuvir is a uridine analogue polymerase inhibitor. Pan-genotypic 
efficacy and safety have been demonstrated in four phase III clinical trials of SOF 
administered with ribavirin (RBV) or with a combination of pegylated interferon alfa 
and RBV (PR). This analysis evaluated the long-term outcomes of SOF/RBV in treat-
ment-naïve (TN) genotype (GT) 1/4/5/6 and TN, treatment-experienced (TE), interferon 
ineligible (TNI) GT 2 and 3 patients MethOds: A Markov-model followed a cohort 
of 10,000 patients for a lifetime, with 50% initiating treatment at the compensated 
cirrhotic stage. In GT 1, 4/5/6 TN patients, SOF/PR for 12 weeks was compared to, 
telaprevir (TVR) or PR, respectively. SOF/RBV for 12 or 16 weeks for GT 2 and 3, respec-
tively, was compared to no treatment for TNI and TE, and PR for 24 or 48 weeks (PR24/
PR48) for TN and TE respectively. SVR 12 weeks have been reported as 90% for TN GT 
1 and 97% for GT 4/5/6 patients; 78% for patients with no treatment option (TNI and 
TE); 97% and 56% for GT 2 and 3 TN; for GT 2 and 3 TE, 86% and 30% with 12-week 
and, 94% and 62% with 16-week regimens, respectively. Results: SOF was shown 
to be highly effective in preventing advanced liver disease (ALD) and mortality due 
to HCV across all GTs. This was particularly favorable for patients with no current 
treatment option (TNI and TE) where up to 7,000 ALD cases can be avoided and more 
than 200 lives saved. The model demonstrated that in GT 1 and 4/5/6 TN patients, 
SOF/PR prevented around 5,000 and 900 more ALD cases than PR and TVR treatment 
arms, respectively. cOnclusiOns: SOF, including within interferon-free regimens, 
was shown to be highly effective in preventing progression to ALD and reducing HCV-
related mortality, particularly in patients with no current treatment option.
Objectives: To conduct pharmacoeconomic analysis of ritonavir-boosted ataza-
navir (ATV/r) vs ritonavir-boosted lopinavir (LPV/r) and ritonavir-boosted darunavir 
(DRV/r) in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in 
treatment-naïve adult patients with HIV-infection from Russian health care sys-
tem point of view. MethOds: Cost-effectiveness analysis (CEA) with calculation of 
incremental cost-effectiveness ratio (ICER) was used for comparison of ATV/r with 
LPV/r. Cost-minimization analysis (CMA) with calculation of cost minimization dif-
ference (CMD) was used for comparison of ATV/r with DRV/r. Direct comparison of 
clinical efficacy and safety of ATV/r vs LPV/r was based on the results of randomized 
controlled trial (RCT) CASTLE. Indirect comparison of clinical efficacy and safety 
of ATV/r with DRV/r was performed on the basis of results of RCTs CASTLE and 
ARTEMIS. Virological response after 96 weeks of treatment and protease inhibitors 
(PIs)-induced diarrhea were considered as clinical efficacy and safety outcomes, 
respectively. Direct medical costs were calculated for the hypothetical cohort of 100 
patients treated for 96 weeks. Results: ATV/r + NRTIs had statistically significant 
higher rate of virological response after 96 weeks of treatment than LPV/r + NRTIs 
(risk ratio (RR) = 1.090 [95% CI 1.002; 1.186], p< 0.05) with statistically significant 
lower risk of PI-induced diarrhea (RR = 0.202 [95% CI 0.107; 0.381], p< 0.0001). There 
were no statistically significant difference between combinations ATV/r + NRTIs 
and DRV/r + NRTIs in terms of rate of virological response and risk of PI-induced 
diarrhea (RR = 0.981 [95% CI 0.869; 1.107], p= 0.77 and 0.543 [95% CI 0.227; 1.296], 
p= 0.17, respectively). ICER for ATV/r vs LPV/r was 4063.58 EUR per one additional 
patient with virological response. CMD for ATV/r vs DRV/r was 5485.38 EUR per 
patient. cOnclusiOns: ATV/r is more preferable than LPV/r and DRV/r for admin-
istration in combination with NRTIs in treatment-naïve adult patients with HIV 
infection.
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Objectives: Herpes Zoster (HZ) is a painful skin rash that occurs most frequently 
among the elderly. A vaccine has recently been licensed in Europe to prevent HZ 
in individuals aged ≥ 50 years. As of today, the actual annual waning-rate (WR) 
of vaccine-induced-immunity (VI) is unknown. To investigate the impact of dif-
ferent WRs on the incremental-cost-effectiveness-ratio (ICER) at different ages at 
vaccination, we performed a health economic analysis for the German statutory-
health-insurance setting. MethOds: Based on a Markov-model, we compared a 
HZ-vaccination-strategy to a scenario without vaccination in Germany targeting 
different cohorts to identify the most efficient age at vaccination (50, 60, or 70 
years). A societal-perspective (SP) was considered, country- and age-specific demo-
graphic, epidemiological, and cost-of-illness input-data were utilized. We assumed 
a vaccine-price of 140.48 Euro/dose and 10 year stable VI. Thereafter an exponential 
waning of VI based on several annual relative WR (0, 2.5, 5, 7.5, 10 and 50%) was 
assumed. All monetary amounts were in Euro 2010. The cycle-length was a quarter; 
we considered a lifelong time-horizon. The discount-rate was 3% for outcomes 
and costs. Results were presented as costs/quality-adjusted life-year (QALY) gained 
ICERs. Results: With annual WR < 5% ICERs increase with age at vaccination from 
50 (0% WR: 16,567€ /QALY gained) to 70 years (0% WR: 37,285€ /QALY gained). When 
WR is ≥ 5% the vaccination-age-specific ICERs become U-shaped with the minimum 
ICERs at 60 years (5% WR: 25,474€ /QALY gained). With high annual WR (50%) the 
ICERs at vaccination-age 70 (50,847€ /QALY) are lower than ICERs at 50 years (56,871€ /
QALY). cOnclusiOns: The annual WR has a high impact on vaccination-age-spe-
cific ICERs. To obtain lowest ICERs, HZ-vaccine should be given early in life (e.g. 50 
years) if WR is low. When annual WR is > 4%, the most efficient age at vaccination is 
60 years. Evidence on the actual WR after HZ-vaccination has yet to be established.
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Objectives: The Netherlands has no varicella vaccination in its National 
Immunization Program (NIP). Although varicella is regarded as a mild disease, imple-
mentation of varicella vaccination in the immunization schedule of several countries 
has shown to be cost-effective. Dutch children are infected with varicella zoster virus 
at younger age and make less use of the health care system as compared to other 
European countries. Therefore, a specific cost-effectiveness study of varicella vac-
cination for The Netherlands is needed. We aimed to estimate the incremental cost-
effectiveness ratio (ICER) of universal vaccination of children against varicella in the 
Dutch NIP as compared with no such vaccination. MethOds: A static cohort model 
was developed to assess the cost-effectiveness of varicella childhood vaccination 
in the first 30 years. Several vaccination strategies were explored by varying the age 
of the booster vaccination. Dutch sources of varicella incidence and health care use 
were combined with vaccine efficacy data from other countries. This study was per-
formed from the societal perspective as well as from the payer’s perspective. Results 
were expressed in euros (€ ) per quality-adjusted life year (QALY) gained. Results: 
Vaccinating a birth-cohort of 180,000 children could avert 105,091 varicella cases and 
save 301.1 QALYs and € 13.7 million of direct and indirect costs. The optimal vacci-
nating-strategy from cost-effectiveness point of view was vaccinating at 14 months 
and 4 years. This scenario resulted in an ICER of € 2844/QALY gained from the societal 
perspective and € 40,582/QALY gained from the health care payer’s perspective, when 
a vaccine price of € 45 was used. Results were sensitive to vaccine price, waning rate of 
the second vaccination and indirect costs. cOnclusiOns: Introduction of varicella 
vaccination in the Dutch NIP would be cost-effective from the societal perspective 
when a threshold of € 20.000/QALY gained was used, which corresponds to the mini-
mum threshold mentioned for the Dutch context.
